FWBI Stock Price, First Wave BioPharma, . Quote, Chart

Market Summary

USD2.96+0.13

Market Closed

4.59%

FWBI Stock Price

View Fullscreen

FWBI RSI Chart

FWBI Valuation

Market Cap

7.3M

Price/Earnings (Trailing)

-1.19

EV/EBITDA

-0.11

Price/Free Cashflow

-0.55

MarketCap/EBT

-0.21

FWBI Price/Earnings (Trailing)

FWBI Profitability

Return on Equity

-38.04%

Return on Assets

-6.76%

Free Cashflow Yield

-181.26%

FWBI Fundamentals

FWBI Earnings

Earnings (TTM)

-6.2M

Earnings Growth (Yr)

236.77%

Earnings Growth (Qtr)

235.76%

Breaking Down FWBI Revenue

Last 7 days

9.6%

Last 30 days

-16.7%

Last 90 days

-47.5%

Trailing 12 Months

-0.7%

How does FWBI drawdown profile look like?

FWBI Financial Health

Current Ratio

1.21

FWBI Investor Care

Shares Dilution (1Y)

2629.38%

Diluted EPS (TTM)

-21.1

Tracking the Latest Insider Buys and Sells of First Wave BioPharma, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	romano sarah	sold	-317	4.2294	-75.00	chief financial officer
Apr 01, 2024	sapirstein james	sold	-735	4.2294	-174	chairman and ceo
Mar 15, 2024	romano sarah	sold	-5,555	4.96	-1,120	chief financial officer
Mar 15, 2024	sapirstein james	sold	-9,359	4.96	-1,887	chairman and ceo
Mar 13, 2024	syage jack	acquired	-	-	15,400	president & coo
Mar 13, 2024	khosla chaitan phd	acquired	-	-	440	-
Jan 12, 2024	romano sarah	sold	-411	4.2	-98.00	chief financial officer
Jan 12, 2024	sapirstein james	sold	-697	4.2	-166	chairman, president and ceo
Jan 02, 2024	coelho mary theresa	acquired	-	-	19,633	-
Jan 02, 2024	riddell alastair	acquired	-	-	19,633	-

Which funds bought or sold FWBI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-15.62	-1,430	10,481	-%
May 15, 2024	ARMISTICE CAPITAL, LLC	new	-	118,260	118,260	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	new	-	48,269	48,269	-%
May 13, 2024	UBS Group AG	sold off	-100	-6,455	-	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	added	116	32.00	57.00	-%
May 08, 2024	US BANCORP \DE\	unchanged	-	-	4.00	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 17, 2024	Kathleen S. Wright Associates Inc.	unchanged	-	-	4.00	-%
Feb 26, 2024	Virtu Financial LLC	sold off	-100	-15,000	-	-%

Are Funds Buying or Selling FWBI?

Are funds buying FWBI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own FWBI

No. of Funds

Unveiling First Wave BioPharma, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	4.99%	78,061	SC 13G/A
Feb 14, 2023	armistice capital, llc	9.99%	740,405	SC 13G

Recent SEC filings of First Wave BioPharma, Inc.

View All Filings

Date Filed	Form Type	Document
May 16, 2024	8-K	Current Report
May 14, 2024	10-Q	Quarterly Report
May 13, 2024	424B5	Prospectus Filed
May 13, 2024	8-K	Current Report
May 10, 2024	PRE 14A	PRE 14A
May 08, 2024	8-K/A	Current Report
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Mar 29, 2024	10-K	Annual Report
Mar 22, 2024	8-K	Current Report

First Wave BioPharma, Inc. News

Latest updates

First Wave BioPharma, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	1224.0%	91,134	6,883	5,927	4,328	5,534	5,440	4,645	3,927	8,825	11,790	12,424	13,777	17,983	12,924	16,722	6,862	8,184	8,903	9,436	9,612	8,957
Current Assets	51.1%	7,490	4,956	3,977	2,354	3,530	3,413	2,549	1,789	6,550	9,425	7,502	8,615	13,170	7,870	11,538	1,601	2,897	3,408	3,730	3,629	2,804
Cash Equivalents	-7.5%	3,432	3,712	3,300	1,200	2,064	1,363	1,700	1,155	5,695	8,249	7,200	8,074	12,026	6,062	11,369	985	1,630	176	1,550	1,311	414
Net PPE	76.8%	26.00	15.00	22.00	29.00	37.00	44.00	51.00	58.00	66.00	73.00	80.00	89.00	92*	18.00	54.00	62.00	74.00	77.00	95.00	108	125
Goodwill	1089.8%	20,039	1,684	1,684	1,684	1,684	1,684	1,715	1,756	1,862	1,912	1,945	1,991	1,974	2,054	1,969	1,890	1,844	1,887	1,833	1,914	1,887
Liabilities	304.5%	13,270	3,280	2,648	3,446	2,821	2,698	6,925	18,117	18,065	19,612	19,394	6,740	3,581	15,565	2,657	7,659	5,143	4,286	6,234	6,664	6,243
Current Liabilities	97.0%	6,173	3,133	2,482	3,261	2,625	2,483	6,694	17,284	14,216	12,300	19,098	6,454	3,575	15,545	2,625	7,616	5,143	4,286	5,819	6,221	5,757
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5,285	2,986	1,077	1,947	1,837	1,728
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,077	-	-	-
Shareholder's Equity	349.2%	16,183	3,603	3,279	882	2,713	2,742	-	-	-	-7,821	6,970	7,037	14,402	-	14,065	-	3,041	4,617	3,202	2,948	2,713
Retained Earnings	3.0%	-178,800	-184,328	-180,200	-176,800	-172,600	-168,533	-164,547	-168,939	-163,500	-153,904	-142,731	-112,330	-103,051	-95,366	-77,965	-72,651	-67,956	-62,694	-61,413	-57,220	-52,177
Additional Paid-In Capital	3.7%	194,944	187,931	183,505	177,675	175,317	171,276	163,722	156,166	155,571	147,307	137,028	120,585	118,693	93,838	93,240	73,124	72,103	68,576	65,969	61,386	56,135
Shares Outstanding	29.7%	2,025	1,561	673	210	77.00	50.00	11.00	4.00	4.00	4.00	2.00	2.00	1.00	741.67*	-	-	-	-	-	-	-
Float	-	-	-	-	6,700	-	-	-	4,500	-	-	-	67,100	-	-	-	25,200	-	-	-	31,400	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-8.9%	-3,746	-3,439	-3,331	-2,761	-2,845	-5,592	-4,254	-4,585	-7,912	-5,862	-15,729	-5,622	-5,073	-5,889	-2,696	-1,343	-1,291	-3,225	-4,153	-4,025	-2,627
Share Based Compensation	115.2%	271	126	263	293	358	84.00	92.00	375	218	102	182	314	772	153	128	177	55.00	33.00	30.00	-	511
Cashflow From Investing	-	88.00	-	-	-	-	-	-	-	-	-10,248	2.00	-73.93	-	90.00	-	2.00	-4.34	-6.85	-3.91	15*	-13.35
Cashflow From Financing	-22.5%	3,379	4,359	5,387	1,933	3,547	5,524	4,772	76.00	5,367	17,073	14,858	1,782	11,051	552	13,060	677	2,756	1,846	4,403	4,928	1,967

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

FWBI Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development expenses	$ 565,962	$ 1,361,683
General and administrative expenses	8,659,692	2,700,742
Total operating expenses	9,225,654	4,062,425
Loss from operations	(9,225,654)	(4,062,425)
Other (expenses) income:
Interest expense	(66,202)	(8,987)
Interest income	228	1,873
Other expense	(653)	(1,114)
Total other expenses	(66,627)	(8,228)
Loss before income tax benefit	(9,292,281)	(4,070,653)
Income tax benefit	14,859,887
Net income (loss)	5,567,606	(4,070,653)
Preferred stock dividends	(66,144)	(87,431)
Net income (loss) applicable to common shareholders	$ 5,501,462	$ (4,158,084)
Basic weighted average shares outstanding	1,761,953	114,033
Diluted weighted average shares outstanding	14,511,461	114,033
Income (loss) per share - basic	$ 3.12	$ (36.46)
Income (loss) per share - diluted	$ 0.38	$ (36.46)

FWBI Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current Assets:
Cash and cash equivalents	$ 3,431,913	$ 3,711,770
Prepaid expenses	4,058,053	1,244,466
Total Current Assets	7,489,966	4,956,236
Property, equipment, and leasehold improvements, net	25,749	14,565
Other Assets:
Restricted cash	21,522	21,522
Patents and tradenames	365,486
In - process R&D	63,000,000
Goodwill	20,038,508	1,684,182
Operating lease right-of-use assets	181,421	195,440
Deposits	11,250	11,250
Total Other Assets	83,618,187	1,912,394
Total Assets	91,133,902	6,883,195
Current Liabilities:
Accounts payable	1,996,519	554,277
Accrued expenses	2,554,446	825,290
Accrued dividend payable	1,135,760	1,069,616
Note payable	386,769	612,784
Operating lease liabilities	71,216	67,111
Other current liabilities	28,546	4,239
Total Current Liabilities	6,173,256	3,133,317
Long - term debt	6,397,889
Deferred tax liability	571,221
Non-current operating lease liabilities	127,592	146,949
Total Liabilities	13,269,958	3,280,266
Mezzanine Equity:
Total Mezzanine Equity	61,681,100
Stockholders' Equity:
Common stock - Par value $0.0001 per share; 100,000,000 shares authorized; 2,025,208 and 1,560,998 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	203	156
Additional paid-in capital	194,943,707	187,931,445
Accumulated deficit	(178,761,066)	(184,328,672)
Total Stockholders' Equity	16,182,844	3,602,929
Total Liabilities, Mezzanine Equity and Stockholders' Equity	91,133,902	6,883,195
Series B Preferred Stock
Stockholders' Equity:
Preferred stock	0	0
Series C Preferred Stock
Stockholders' Equity:
Preferred stock	0	0
Series D Preferred Stock
Stockholders' Equity:
Preferred stock	0	0
Series E Preferred Stock
Stockholders' Equity:
Preferred stock	0	0
Series F Preferred Stock
Stockholders' Equity:
Preferred stock	0	$ 0
Series G Preferred Stock
Mezzanine Equity:
Total Mezzanine Equity	$ 61,681,100

About First Wave BioPharma, Inc.

First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; and niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.

CEO	Mr. James R. Sapirstein M.B.A., R.Ph.
WEBSITE	firstwavebio.com
INDUSTRY	Biotechnology
EMPLOYEES	10

First Wave BioPharma, Inc. Frequently Asked Questions

What is the ticker symbol for First Wave BioPharma, Inc.? What does FWBI stand for in stocks?

FWBI is the stock ticker symbol of First Wave BioPharma, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of First Wave BioPharma, Inc. (FWBI)?

As of Thu May 16 2024, market cap of First Wave BioPharma, Inc. is 7.33 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FWBI stock?

You can check FWBI's fair value in chart for subscribers.

What is the fair value of FWBI stock?

You can check FWBI's fair value in chart for subscribers. The fair value of First Wave BioPharma, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of First Wave BioPharma, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for FWBI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is First Wave BioPharma, Inc. a good stock to buy?

The fair value guage provides a quick view whether FWBI is over valued or under valued. Whether First Wave BioPharma, Inc. is cheap or expensive depends on the assumptions which impact First Wave BioPharma, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FWBI.